Search tips
Search criteria 


Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. 2001 February; 84(3): 435–440.
PMCID: PMC2363744

Incidence of multiple primary cancers in a cohort of women diagnosed with breast cancer in southeast England


Among women in the Thames Cancer Registry database with a first breast cancer diagnosed between 1961–1995 observed numbers of subsequent cancers were compared with expected numbers and standardized incidence ratios were calculated. The occurrence of breast cancers subsequent to cancers at other sites was also examined. Women diagnosed with breast cancer before age 50 had significantly elevated risks for 9 cancer sites namely, oesophagus, stomach, lung, bone, connective tissue, breast, corpus uteri, ovary and myeloid leukaemia compared with 2 sites (corpus uteri and myeloid leukaemia) in women diagnosed at age 50 and above. Some of these associations are consistent with the effects of known inherited cancer susceptibility genes, shared environmental factors, or therapy. © 2001 Cancer Research Campaign

Keywords: multiple primary cancers, cancer genetics, registries, breast cancer

Full Text

The Full Text of this article is available as a PDF (108K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Adami HO, Bergkvist L, Krusemo U, Persson I. Breast cancer as a risk factor for other primary malignant diseases. A nationwide cohort study. J Natl Cancer Inst. 1984 Nov;73(5):1049–1055. [PubMed]
  • Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen therapy and radiotherapy for early breast cancer. J Natl Cancer Inst. 1991 Jul 17;83(14):1013–1017. [PubMed]
  • Bevan S, Houlston RS. Genetic predisposition to gastric cancer. QJM. 1999 Jan;92(1):5–10. [PubMed]
  • De Vivo I, Gertig DM, Nagase S, Hankinson SE, O'Brien R, Speizer FE, Parsons R, Hunter DJ. Novel germline mutations in the PTEN tumour suppressor gene found in women with multiple cancers. J Med Genet. 2000 May;37(5):336–341. [PMC free article] [PubMed]
  • Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet. 1995 Jan;56(1):265–271. [PubMed]
  • Eeles RA. Germline mutations in the TP53 gene. Cancer Surv. 1995;25:101–124. [PubMed]
  • Ewertz M, Mouridsen HT. Second cancer following cancer of the female breast in Denmark, 1943-80. Natl Cancer Inst Monogr. 1985 Dec;68:325–329. [PubMed]
  • FitzGerald MG, Bean JM, Hegde SR, Unsal H, MacDonald DJ, Harkin DP, Finkelstein DM, Isselbacher KJ, Haber DA. Heterozygous ATM mutations do not contribute to early onset of breast cancer. Nat Genet. 1997 Mar;15(3):307–310. [PubMed]
  • Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Lancet. 1994 Mar 19;343(8899):692–695. [PubMed]
  • Freihoff D, Kempe A, Beste B, Wappenschmidt B, Kreyer E, Hayashi Y, Meindl A, Krebs D, Wiestler OD, von Deimling A, et al. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br J Cancer. 1999 Feb;79(5-6):754–758. [PMC free article] [PubMed]
  • Gail MH, Costantino JP, Bryant J, Croyle R, Freedman L, Helzlsouer K, Vogel V. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst. 1999 Nov 3;91(21):1829–1846. [PubMed]
  • Harvey EB, Brinton LA. Second cancer following cancer of the breast in Connecticut, 1935-82. Natl Cancer Inst Monogr. 1985 Dec;68:99–112. [PubMed]
  • Houlston RS, Stratton MR. Genetics of non-medullary thyroid cancer. QJM. 1995 Oct;88(10):685–693. [PubMed]
  • Inskip HM, Kinlen LJ, Taylor AM, Woods CG, Arlett CF. Risk of breast cancer and other cancers in heterozygotes for ataxia-telangiectasia. Br J Cancer. 1999 Mar;79(7-8):1304–1307. [PMC free article] [PubMed]
  • Kollmannsberger C, Hartmann JT, Kanz L, Bokemeyer C. Risk of secondary myeloid leukemia and myelodysplastic syndrome following standard-dose chemotherapy or high-dose chemotherapy with stem cell support in patients with potentially curable malignancies. J Cancer Res Clin Oncol. 1998;124(3-4):207–214. [PubMed]
  • Liaw D, Marsh DJ, Li J, Dahia PL, Wang SI, Zheng Z, Bose S, Call KM, Tsou HC, Peacocke M, et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat Genet. 1997 May;16(1):64–67. [PubMed]
  • Palmer JR, Rosenberg L. Cigarette smoking and the risk of breast cancer. Epidemiol Rev. 1993;15(1):145–156. [PubMed]
  • Peto J, Easton DF, Matthews FE, Ford D, Swerdlow AJ. Cancer mortality in relatives of women with breast cancer: the OPCS Study. Office of Population Censuses and Surveys. Int J Cancer. 1996 Jan 26;65(3):275–283. [PubMed]
  • Peto J, Collins N, Barfoot R, Seal S, Warren W, Rahman N, Easton DF, Evans C, Deacon J, Stratton MR. Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer. J Natl Cancer Inst. 1999 Jun 2;91(11):943–949. [PubMed]
  • Prior P, Waterhouse JA. Multiple primary cancers of the breast and ovary. Br J Cancer. 1981 Nov;44(5):628–636. [PMC free article] [PubMed]
  • Ron E, Curtis R, Hoffman DA, Flannery JT. Multiple primary breast and thyroid cancer. Br J Cancer. 1984 Jan;49(1):87–92. [PMC free article] [PubMed]
  • Schimke RN. Genetic aspects of multiple endocrine neoplasia. Annu Rev Med. 1984;35:25–31. [PubMed]
  • Swift M, Reitnauer PJ, Morrell D, Chase CL. Breast and other cancers in families with ataxia-telangiectasia. N Engl J Med. 1987 May 21;316(21):1289–1294. [PubMed]
  • Teppo L, Pukkala E, Saxén E. Multiple cancer--an epidemiologic exercise in Finland. J Natl Cancer Inst. 1985 Aug;75(2):207–217. [PubMed]
  • Vassilopoulou-Sellin R, Palmer L, Taylor S, Cooksley CS. Incidence of breast carcinoma in women with thyroid carcinoma. Cancer. 1999 Feb 1;85(3):696–705. [PubMed]
  • Volk N, Pompe-Kirn V. Second primary cancers in breast cancer patients in Slovenia. Cancer Causes Control. 1997 Sep;8(5):764–770. [PubMed]
  • Warren W, Eeles RA, Ponder BA, Easton DF, Averill D, Ponder MA, Anderson K, Evans AM, DeMars R, Love R, et al. No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families. Oncogene. 1992 May;7(5):1043–1046. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK